Brian P. Murray, MD

home / authors / brian-p-murray-md

Articles

Comparing Direct Medical Costs of OnabotulinumtoxinA With Other Common Overactive Bladder Interventions

Alon Yehoshua, PharmD, MS;Brian P. Murray, MD;Sandip P. Vasavada, MD;Peter K. Sand, MD

February 2nd 2018

This cost analysis demonstrated that onabotulinumtoxinA is one of the least-costly treatment options for inadequately managed overactive bladder syndrome.

Published: June 10th 2025 | Updated: June 12th 2025

Department of Health and Human Services Reconstitutes ACIP, Removing 17 Sitting Members

Published: June 2nd 2025 | Updated: June 11th 2025

NLA 2025: Managing Omega-3 Therapy With Statins, PCSK9 Inhibitors for Cardiovascular Care

Published: June 3rd 2025 | Updated: June 11th 2025

ASCO 2025: Zongertinib Shows Strong Potential in HER2-Mutant NSCLC Treatment Landscape

Published: May 30th 2025 | Updated: June 5th 2025

Emerging Data: Impacts of ROCKstar and AGAVE-201

Mother holding baby's foot with measles spots | Image Credit: © rostock-studio - stock.adobe.com

Published: April 18th 2025 | Updated: April 21st 2025

Measles Cases Climb to 800 in United States as Outbreak Spreads Across Borders

Anatomy of Human Heart on medical background. 3d render - Image credit: ckybe | stock.adobe.com

Published: March 10th 2025 | Updated: March 21st 2025

Pharmacists Will Play an Essential Role in Optimizing Vutrisiran Therapy for ATTR-CM

Do Not Sell My Information

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

Brian P. Murray, MD

Articles

Latest Updated Articles